Cubist closes on Trius buyout; Investigators launch study on cancer therapy; Vaccine clears HIV-like virus in monkey study;

@FierceBiotech: ICYMI yesterday--Industry Voices: Breakthrough designation Q&A via Michelle Rohrer. Commentary | Follow @FierceBiotech

@JohnCFierce: I think the patient perspective many news orgs have fundamentally corrupts coverage of animal studies. Article | Follow @JohnCFierce

@EmilyMFierce: Genia Technologies, Columbia, Harvard nab $5.3M NIH grant for genome sequencing. More from FierceBiotech Research | Follow @EmilyMFierce

@Ry_McBride: I'm talking to Treato (social listening for pharma) later today. Stay tuned for post at FierceBiotech IT. | Follow @Ry_McBride

> Cubist ($CBST) has closed on its $704 million buyout of Trius Therapeutics. Now Trius' 100 staffers will find out whether they'll be keeping their jobs or not. Story

> TGen and Scottsdale Healthcare have begun a human study of a new therapy for pancreatic cancer that was adapted from the Asian "Thunder God vine." Story

Medical Device News

@FierceMedDev: Gore's endovascular graft-repair device gains wider FDA nod. Item | Follow @FierceMedDev

@DamianFierce: St. Jude is riding into India with a new pacemaker and a plan to boost sales. Story | Follow @DamianFierce

@MarkHFierce: We have a new round of stories at FierceDiagnostics. Check them out | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Civitas corrals $38M for inhaled Parkinson's treatment. More from FierceDrugDelivery | Follow @MichaelGFierce

> Ariosa targets Brazil with prenatal Dx. Article

> InVivo slides again as CFO bolts, spinal study pends. Report

> J&J feels Decision Diagnostics' sting in glucose strip patent fight. News

Pharma News

@FiercePharma: China's state TV broadcasts corruption allegations against Sino Biopharm, first domestic drugmaker publicly tagged in bribery probe. | Follow @FiercePharma

@CarlyHFierce: Second recall in as many weeks for J&J--this time, a moldy schizophrenia drug is the culprit. More from FiercePharmaManufacturing | Follow @CarlyHFierce

> Patch maker LTS Lohmann collecting first-round bids in possible €1.4B deal. Report

> Bristol-Myers' Yervoy hopes snag on flubbed prostate cancer trial. Story

> China's Sino Biopharm reels after CCTV accuses unit of bribing doctors. More

> Botox approval for crow's feet provides bit of upbeat news for beleaguered Allergan. Article

Pharma Manufacturing News

@EricPFierce: South Africa's Aspen says manufacturing assets it is getting from GSK, Merck part of global push. Story | Follow @EricPFierce

> J&J recall streak continues with moldy schizophrenia drug. News

> Eisai U.K. site OK'd to make Fycompa. Report

> Merged CFR, Adcock Ingram to have 18 manufacturing sites. Article

> KKR deal in Gland Pharma calls for $100M plant investment. Item

> Pharma packaging growing market with openings for good ideas. More

Vaccines News

> Meningitis cases fall 94% following vaccine introduction. Report

> Low uptake of Merck's Zostavax costing healthcare systems. Item

> Early-phase HIV vaccines advance on positive data. News

> Implant aims to end logistical challenges of cancer vaccines. More

> Pfizer details plans to expand vaccine portfolio beyond Prevnar. Article

> PhIII data dents GSK's hopes for cancer vaccine. Story

And Finally… Researchers say that a new vaccine based on the CMV virus cleared an HIV-like virus from about half of the monkeys it was tested on. Report

Suggested Articles

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.

The readout is a key moment in the history of the drug and Mirati, shares in which have soared in the updraft created by data on Amgen’s rival asset.